Location Seattle, Washington, United States Regions Greater Seattle Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Prior to joining C3 Jian, Todd Patrick served as President and Chief Operating Officer and joined the Board of Directors of ID Biomedical Corporation after the Company elected in 1998 to exit its core diagnostic business to focus on vaccines. Mr. Patrick started ID Biomedical’s vaccine subsidiary in 1994. In September 2005, GlaxoSmithKline
purchased ID Biomedical for approximately $1.5 billion plus the assumption of $200 million in debt. To date, the GSK/IDB merger is the second largest “pure play” enterprise value M&A transaction in the history of the vaccine industry.
After retiring from ID Biomedical, Mr. Patrick and a group of investors raised approximately $100 million for a portfolio of small medical companies. Mr. Patrick was a director of each of these companies and also acted as a consultant for these and other biotech companies prior to ending his retirement to join C3 Jian.
Before he joined ID Biomedical, Mr. Patrick was appointed the first ever Director of the Office of Intellectual Property Administration at UCLA, helping the organization start its IP program in 1989.
Mr. Patrick serves as Chairman of the Board of Trustees for the Seattle Biomedical Research Institute, a 400 person, non-profit global health organization focused on creating new drugs and vaccines to treat infectious diseases in the developing world.
He is a past trustee of a variety of organizations in the Pacific Northwest, including the Washington Biotechnology and Biomedical Association (WBBA), and the WSU Research Foundation.
Mr. Patrick received his BA from the University of Washington and an MBA from Washington State University.
